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Background: Multiple studies of improved glycemic control
in critically ill patients have yielded contradictory results.
Few studies on inpatient hyperglycemia exist in the BMT
population. We undertook a quality improvement project to
improve blood glucose (BG) control with a goal of increasing
the proportion of time that patients on our BMTservice spent
within the range of 70-200 mg/dl.
Methods: With the Division of Endocrinology, an algorithm
for the initiation and modiﬁcation of ﬁnger sticks and anti-
hyperglycemic medications was created and implemented
on the Tufts Medical Center BMT service for admissions
between 4/1-6/30/13 that were predicted to be > 48 hours
in duration (intervention). Using the Remote Automated
Laboratory System (RALS), the percent of time in each BG
range (<70, 71-110, 111-140, 141-199, >200) was calculated
for the entire ﬂoor in the three months prior to imple-
mentation(baseline) and during the threemonths of the pilot
program. As the oncology service is included in thiscalculation and was not part of our intervention, admissions
were analyzed for comparison. With IRB approval, retro-
spective data of admissions >48 hours was collected to
evaluate BG, length of stay, and infectious complications.
Results: The baseline cohort included 64 BMT admissions,
while there were 70 BMT admissions in the intervention
cohort and 102 oncology admissions not part of the inter-
vention. 14% of patients in each of the three admission
groups had a history of diabetes. 30% of all patients on BMT
were discharged on steroids, compared to 10% on oncology.
On admissions when ﬁnger stick evaluation of BG was
initiated (36% in the BMT intervention cohort, 25% in the
BMT baseline corhort, (P ¼ 0.25), more patients received
short acting insulin as per the algorithm (21% vs 6%, P ¼
0.016), but there was no difference in the number transi-
tioned to long acting insulin. In the intervention cohort, the
proportion of time spent in the BG range of 71-199 increased,
with less time spent with a BG < 70 or > 200 (Figure 1, P <
0.0001). Fewer BMT patients were hyperglycemic within 48
hours of a documented infection in the intervention group
compared to the baseline cohort, but the overall rate of
infection among the three groups was low. Within each
cohort on BMT, 6 admissions had a discharge BG>200, and 3
were discharged on new anti-hyperglycemic medications.
Conclusions: We were able to demonstrate the feasibility of
implementing a program to control and track blood glucose.
Not only were we able to limit hypoglycemic episodes, there
was a lower rate during the intervention compared to baseline.
The results of this retrospective study will allow the design of
larger trials to determinewhether BG control has an impact on
length of stay, infectious complications, and mortality.307
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